



**Bonfiglio F, Brusca A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. *Blood*. 2022;139(5):732-747.**

Page 733: In the abstract, the sentence “We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor metadata and in genetically modified mouse models, and determined correlations with outcome data” should read “We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor metadata and determined correlations with outcome data.”

At the time of publication, the supplemental figures were absent from supplemental File 1.

The errors have been corrected in the online version of the article.

<https://doi.org/10.1182/blood.2023019847>

© 2023 by The American Society of Hematology

---

**Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. *Blood*. 2022;140(8):927-931.**

In the byline on page 927, “Matthew T. Koster” should read “Matthew J. Koster.”

<https://doi.org/10.1182/blood.2023019982>

© 2023 by The American Society of Hematology